Verve Therapeutics (VERV) executive Lister received 225,000 Stock Option (right to buy)

Insider transactions reported

Troy Lister (Chief Scientific Officer at Verve Therapeutics Inc., VERV) reported that they received 225,000 Stock Option (right to buy) on Jan 8, 2025.

Reporting person

Lister Troy

Role

Chief Scientific Officer

Options and other derivatives

Holdings before and after

• Stock Option (right to buy): 0 to 225,000 direct
• Restricted Stock Units: 0 to 40,000 direct

Footnotes from the filing

1. 1. The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.
2. 2. Each restricted stock unit represents a contingent right to receive one share of common stock.
3. 3. On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ